Paediatric Rheumatology Unit, Paediatrics Department, Universidade Federal de Sao Paulo, Doutor Bacelar Street, 173, 12 Floor, Sao Paulo, SP, 04026-000, Brazil.
Division of Rheumatology, Department of Medicine, Universidade Federal de Sao Paulo, Sao Paulo, Brazil.
Adv Rheumatol. 2022 Jul 25;62(1):28. doi: 10.1186/s42358-022-00260-5.
The observation that 2-deoxy-2[18F]fluoro-D-glucose-positron emission tomography/magnetic resonance imaging ([18F]F-FDG-PET/MRI) revealed high-grade arterial wall FDG uptake, without arterial wall thickening with contrast-enhancement, in a considerable number of c-TA patients in our previous study, encouraged us to compare patients with both PET and MR angiography (MRA) positives, with those with PET positive but MRA negative. Our aim was to evaluate the relevance of these two imaging modalities together.
A three-center cross-sectional study with 17 patients who fulfilled the EULAR/PRINTO/PReS criteria for c-TA and who underwent [18F]F-FDG-PET/MRI was previously performed. Herein we compared patients/vessels with positive PET (arterial wall F-FDG uptake higher than liver) and positive MRA (arterial wall thickening with contrast-enhancement)-group 1, with those with positive PET but negative MRA-group 2.
Median disease duration of 17 c-TA patients was 10.4 years. Nine patients were classified as group 1 and six as group 2. Median of metabolic inflammatory volume (MIV) of all arterial segments was significantly higher in group 1 (2346 vs. 1177 cm; p = 0.036). Fifty-four (19%) from 284 available arterial segments presented positive findings in vessel wall in one or both images. Positive findings were concordant between PET and MRA in only 13% arterial segments (group 1); most changes (28-59.6%) that were discordant between both images, were positive in PET and negative in MRA (group 2).
Our study demonstrated that [18F]F-FDG-PET/MRI added information about inflammation in vessel wall of c-TA patients. Prospective multicenter studies are needed in order to get solid data to guide immunosuppressive tapering and withdrawal.
在我们之前的研究中,相当数量的 c-TA 患者的 2-脱氧-2[18F]氟-D-葡萄糖正电子发射断层扫描/磁共振成像([18F]F-FDG-PET/MRI)显示高等级动脉壁 FDG 摄取,而没有对比增强的动脉壁增厚,这一观察结果促使我们比较 PET 和磁共振血管造影(MRA)均阳性的患者与 PET 阳性但 MRA 阴性的患者。我们的目的是评估这两种成像方式的相关性。
此前进行了一项三中心横断面研究,纳入了 17 名符合 c-TA 的 EULAR/PRINTO/PReS 标准并接受[18F]F-FDG-PET/MRI 检查的患者。在此,我们比较了 PET 和 MRA 均阳性的患者/血管(动脉壁 F-FDG 摄取高于肝脏)与仅 PET 阳性而 MRA 阴性的患者(组 2)。
17 名 c-TA 患者的中位疾病持续时间为 10.4 年。9 名患者被分为组 1,6 名患者被分为组 2。所有动脉节段的代谢炎症体积(MIV)中位数在组 1 中明显更高(2346 比 1177cm;p=0.036)。在 284 个可评估的动脉节段中,54 个(19%)在一个或两个图像中呈现血管壁阳性结果。在 PET 和 MRA 中,只有 13%的动脉节段(组 1)的阳性结果是一致的;在这两种图像之间存在差异的大多数变化(28-59.6%),在 PET 中是阳性的,而在 MRA 中是阴性的(组 2)。
我们的研究表明,[18F]F-FDG-PET/MRI 提供了关于 c-TA 患者血管壁炎症的信息。需要进行前瞻性多中心研究,以获得可靠的数据来指导免疫抑制药物的逐渐减少和停药。